This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia.
Investigator's sites: 60 sites in Germany.
Primary objectives:
* Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy
AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
Age ≥ 18 years. There is no upper age limit.
Signed written informed consent
there are no exclusion criteria
Patients with newly-diagnosed AML, including acute promyelocytic leukemia (APL)
Case-only
Prospective
Not listed
Epidemiological parameters
Epidemiological parameters
Relapse free survival (RFS)
Relapse free survival
Time to relapse (TTR),
Time to relapse (TTR),
Overall Survival (OS)
Overall Survival (OS)
Complete Remission (CR)
Complete Remission
Treatment related mortality (TRM)
Treatment related mortality
Therapy-associated morbidity
grade IV toxicities
Recording and evaluating the quality of therapy and diagnosis
Recording and evaluating the quality of therapy and diagnosis
Click on the lead sponsor to view all of their trials.
